NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $679,000 | +4.6% | 37,800 | 0.0% | 0.02% | +9.1% |
| Q2 2021 | $649,000 | +3.3% | 37,800 | +20.4% | 0.02% | -12.0% |
| Q1 2021 | $628,000 | +17.6% | 31,400 | 0.0% | 0.02% | +8.7% |
| Q4 2020 | $534,000 | -12.0% | 31,400 | -14.2% | 0.02% | -20.7% |
| Q3 2020 | $607,000 | -37.4% | 36,600 | -12.6% | 0.03% | -37.0% |
| Q2 2020 | $970,000 | +29.7% | 41,900 | 0.0% | 0.05% | +2.2% |
| Q1 2020 | $748,000 | +14.7% | 41,900 | +38.7% | 0.04% | +66.7% |
| Q4 2019 | $652,000 | +167.2% | 30,200 | +125.4% | 0.03% | +145.5% |
| Q3 2019 | $244,000 | -52.1% | 13,400 | -6.3% | 0.01% | -50.0% |
| Q2 2019 | $509,000 | +5.2% | 14,300 | -0.7% | 0.02% | +4.8% |
| Q1 2019 | $484,000 | +2.3% | 14,400 | 0.0% | 0.02% | -8.7% |
| Q4 2018 | $473,000 | -46.1% | 14,400 | 0.0% | 0.02% | -30.3% |
| Q3 2018 | $878,000 | +21.4% | 14,400 | -2.7% | 0.03% | +17.9% |
| Q2 2018 | $723,000 | -55.8% | 14,800 | -3.9% | 0.03% | -54.8% |
| Q1 2018 | $1,636,000 | – | 15,400 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 598,400 | $10,083,000 | 3.98% |
| Opus Point Partners Management, LLC | 348,583 | $5,874,000 | 3.88% |
| Camber Capital Management LP | 3,500,000 | $58,975,000 | 3.81% |
| 1492 Capital Management LLC | 180,601 | $3,043,000 | 2.21% |
| Virtus ETF Advisers LLC | 38,260 | $645,000 | 1.77% |
| Cormorant Asset Management, LP | 765,156 | $12,893,000 | 1.54% |
| Rhenman & Partners Asset Management AB | 581,000 | $9,790,000 | 1.48% |
| Granahan Investment Management | 2,082,155 | $35,084,000 | 1.21% |
| BRIDGER MANAGEMENT, LLC | 1,563,862 | $26,351,000 | 0.87% |
| RICE HALL JAMES & ASSOCIATES, LLC | 899,531 | $15,157,000 | 0.87% |